Prosecution Insights
Prosecution Insights
1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
"Micar Innovation" Ltd. has a point of activity in its patent prosecution with 1 pending office action. This action is assigned to a distinct examiner, BRENDA LIBBY COLEMAN. As the busiest examiner for the company, BRENDA LIBBY COLEMAN is responsible for the 1 pending office action currently recorded.
The data shows 0 distinct art units for this portfolio, indicating a specific or early-stage classification for the pending matter. With a pending office action and a distinct examiner, the company's current patenting efforts are focused on a specific technical disclosure. This streamlined profile suggests a targeted intellectual property objective. The 0 distinct art units highlight the unique nature of this filing.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COLEMAN, BRENDA LIBBY | 1 | 74.9% | +15.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18852066 | PAN-CHEMOKINE ANTAGONISTS FOR USE IN TREATING CANCER AND IMMUNE DISORDERS | COLEMAN, BRENDA LIBBY | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18852066 | PAN-CHEMOKINE ANTAGONISTS FOR USE IN TREATING CANCER AND IMMUNE DISORDERS | COLEMAN, BRENDA LIBBY | — | §112 | Non-Final OA | — | Pending | Sep 27, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial